{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:29:57Z","timestamp":1761863397212},"reference-count":12,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.bulcan.2014.12.007","type":"journal-article","created":{"date-parts":[[2015,1,21]],"date-time":"2015-01-21T20:22:20Z","timestamp":1421871740000},"page":"53-56","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Le point sur la pr\u00e9disposition g\u00e9n\u00e9tique pour le cancer de la prostate"],"prefix":"10.1016","volume":"102","author":[{"given":"Olivier","family":"Cussenot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9raldine","family":"Cancel-Tassin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.bulcan.2014.12.007_bib0005","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/ng.3094","article-title":"A meta-analysis of 87,040\u00a0individuals identifies 23\u00a0new susceptibility loci for prostate cancer","volume":"46","author":"Al Olama","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.bulcan.2014.12.007_bib0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0953-6205(00)00136-9","article-title":"Heterogeneity in genetic susceptibility to prostate cancer","volume":"12","author":"Cussenot","year":"2001","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.bulcan.2014.12.007_bib0015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00439-012-1229-4","article-title":"HOXB13\u00a0is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG)","volume":"132","author":"Xu","year":"2013","journal-title":"Hum Genet"},{"key":"10.1016\/j.bulcan.2014.12.007_bib0020","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/bjc.2014.30","article-title":"Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease","volume":"110","author":"Leongamornlert","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bulcan.2014.12.007_bib0025","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2014.12.007_bib0030","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0022-5347(05)64663-0","article-title":"Targeted screening for prostate cancer in high risk families: early onset is a significant risk factor for disease in first degree relatives","volume":"168","author":"Valeri","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.bulcan.2014.12.007_bib0035","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1684\/bdc.2013.1739","article-title":"Pharmaco- and diet-based prostate cancer prevention","volume":"100","author":"Eisinger","year":"2013","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2014.12.007_bib0040","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.1158\/1078-0432.CCR-07-4999","article-title":"Effect of genetic variability within 8q24\u00a0on aggressiveness patterns at diagnosis and familial status of prostate cancer","volume":"14","author":"Cussenot","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2014.12.007_bib0045","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jnci\/djr500","article-title":"Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13\u00a0years of follow-up","volume":"104","author":"Andriole","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bulcan.2014.12.007_bib0050","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate cancer mortality in a randomized European study","volume":"360","author":"Schr\u00f6der","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2014.12.007_bib0055","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.juro.2014.07.085","article-title":"Impact of family history on prostate cancer mortality in white men undergoing PSA-based screening","volume":"193","author":"Liss","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.bulcan.2014.12.007_bib0060","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.eururo.2014.01.003","article-title":"Targeted prostate cancer screening in BRCA1\u00a0and BRCA2\u00a0mutation carriers: results from the initial screening round of the IMPACT Study","volume":"66","author":"Bancroft","year":"2014","journal-title":"Eur Urol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455114000083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455114000083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T23:34:15Z","timestamp":1566257655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455114000083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0007455114000083"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2014.12.007","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Le point sur la pr\u00e9disposition g\u00e9n\u00e9tique pour le cancer de la prostate","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2014.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}